This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, L. Articles by Carbone, D. P. Search for Related Content PubMed PubMed Citation Articles by Yang, L. Articles by Carbone, D. P.

Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism

Departments of ¹ Medicine and ² Cancer Biology and ³ The Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee and ⁴ Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto, Japan

Requests for reprints: Li Yang, Vanderbilt University Medical Center, 646 PRB, 2220 Pierce Avenue, Nashville, TN 37232. Phone: 615-936-3320; Fax: 615-936-1790; E-mail: li.yang{at}vanderbilt.edu.

Prostaglandin E₂ (PGE₂), one of the major metabolites of cyclooxygenase-2, has been implicated in tumorigenesis and tumor progression in several human cancers, including colorectal and lung. Here, we show that one of the PGE₂ receptors, the EP4 receptor, plays an important role in metastasis in both of these tumor types. Using i.v. injected Lewis lung carcinoma (3LL), we found that tumor metastasis to lung was significantly reduced when mice were treated with a specific EP4 antagonist ONO-AE3-208 or when EP4 receptor expression was knocked down in the tumor cells using RNA interference technology. Host EP4 receptors also contributed to tumor metastasis and tumor growth with decreased metastasis and tumor growth observed in EP4 receptor knockout animals. In vitro tumor cell adhesion, motility, invasion, colony formation, and Akt phosphorylation were all significantly inhibited when 3LL cells were treated with the EP4 receptor–specific antagonist. When the cells were treated with an EP4-specific agonist (AE1-734), we observed a worsening of these same features in vitro. Treatment with ONO-AE3-208 also profoundly decreased liver metastases after intrasplenic injection of MC26 colon cancer cells. Our data show that selective antagonism of EP4 receptor signaling results in a profound reduction in lung and colon cancer metastasis. Selective antagonism of the EP4 receptor may thus represent a novel therapeutic approach for the treatment of cancer and especially its propensity to metastasize. (Cancer Res 2006; 66(19): 9665-72)

This article has been cited by other articles:

				M. G. Backlund, J. M. Amann, and D. H. Johnson Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids J. Clin. Oncol., February 20, 2008; 26(6): 825 - 827. [Full Text] [PDF]

				C. H. Serezani, J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden Prostaglandin E2 Suppresses Bacterial Killing in Alveolar Macrophages by Inhibiting NADPH Oxidase Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 562 - 570. [Abstract] [Full Text] [PDF]

				R. Rao, R. Redha, I. Macias-Perez, Y. Su, C. Hao, R. Zent, M. D. Breyer, and A. Pozzi Prostaglandin E2-EP4 Receptor Promotes Endothelial Cell Migration via ERK Activation and Angiogenesis in Vivo J. Biol. Chem., June 8, 2007; 282(23): 16959 - 16968. [Abstract] [Full Text] [PDF]

				S. Han, J. D. Ritzenthaler, B. Wingerd, H. N. Rivera, and J. Roman Extracellular Matrix Fibronectin Increases Prostaglandin E2 Receptor Subtype EP4 in Lung Carcinoma Cells through Multiple Signaling Pathways: THE ROLE OF AP-2 J. Biol. Chem., March 16, 2007; 282(11): 7961 - 7972. [Abstract] [Full Text] [PDF]